The details of the Phase 3 CAPITAN CVOT study are provided below. It will evaluate 25 mg plozasiran versus placebo in two cohorts: a secondary prevention cohort with triglyceride (TG) levels 200 ...

The combination of tec and daratumumab (tec-dara) in the phase 1b TRIMM-2 study (NCT04108195) was also well-tolerated with promising efficacy. MajesTEC-3 (NCT05083169) is a multicenter, open-label, ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of ...